• 제목/요약/키워드: Famciclovir

검색결과 10건 처리시간 0.025초

Famciclovir에 반응하지 않는 소양인(少陽人) 대상포진(帶狀疱疹) 환자의 양독백호탕(陽毒白虎湯), Famciclovir 병용 치료로 호전된 1례 (A Case Report of Soyangin Herpes Zoster Patient who does not Respond to Famciclovir Treated with Combined Medication of Yangdokbackho-tang and Famciclovir)

  • 권태욱;노기환
    • 대한중풍순환신경학회지
    • /
    • 제13권1호
    • /
    • pp.71-76
    • /
    • 2012
  • In this case, patient diagnosed as herpes zoster was given Famciclovir for 5 days but did not respond. The patient was then confirmed as Soyangin and given combined medication of Yangdokbackho-tang and Famciclovir and showed remarkable improvement in vesicles and his pain. Most of symptoms were gone after 10 days of combined medication. We used Visual Analogue Scale(VAS) and pictures of the affected part for the assessment and report this case.

  • PDF

팜비어 정 250밀리그람(팜시클로버 250 mg)에 대한 팜시버 정의 생물학적동등성 (Bioequivalence of Famcivir Tablet to FamvirTM Tablet 250 mg (Famciclovir 250 mg))

  • 강현아;조혜영;오인준;이명희;이용복
    • Journal of Pharmaceutical Investigation
    • /
    • 제35권4호
    • /
    • pp.295-301
    • /
    • 2005
  • Famciclovir is an oral prodrug of the antiherpesvirus nucleoside analogue, penciclovir. In human, famciclovir is orally well absorbed and then undergoes extensive first pass metabolism to penciclovir and essentially no parent compound is recovered from plasma or urine. The purpose of the present study was to evaluate the bioequivalence of two famciclovir tablets, $Famvir^{TM}$ tablet 250 mg (Novartis Korea Ltd.) and Famcivir (Hanmi Pharmaceutical Co., Ltd.), according to the guidelines of the Korea Food and Drug Administration (KFDA). The release of famciclovir from the two famciclovir formulations in vitro was tested using KP VIII Apparatus II method with water. Twenty six healthy male subjects, $24.19{\pm}2.08$ years in age and $71.55{\pm}6.89$ kg in body weight, were divided into two groups and a randomized $2{\times}2$ cross-over study was employed. After a single tablet containing 250 mg as famciclovir was orally administered, blood samples were taken at predetermined time intervals and the concentrations of penciclovir in serum were determined using HPLC with UV detector. The dissolution profiles of two formulations were similar at water. In addition, the pharmacokinetic parameters such as $AUC_t$, $C_{max}$ and $T_{max}$ were calculated and ANOVA test was utilized for the statistical analysis of the parameters using logarithmically transformed $AUC_t$, $C_{max}$ and untransformed $T_{max}$. The results showed that the differences between two formulations based on the reference drug, $Famvir^{TM}$ tablet 250 mg, were -2.93, -8.02 and 10.47% for $AUC_t$, $C_{max}$ and $T_{max}$, respectively. There were no sequence effects between two formulations in these parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log0.8 to log1.25 (e.g., $log0.92{\sim}log1.01$ and $log0.85{\sim}log1.00$ for $AUC_t$ and $C_{max}$, respectively). Thus, the criteria of the KFDA bioequivalence guideline were satisfied, indicating Famcivir was bioequivalent to $Famvir^{TM}$ tablet 250 mg.

팜비어 정 750밀리그람(팜시클로버 750밀리그람)에 대한 팜시버 정 750밀리그람의 생물학적동등성 (Bioequivalence of Famvir Tablet 750 mg to Famcivir Tablet 750 mg (Famciclovir 750 mg))

  • 김세미;윤화;류희두;김경란;강현아;조혜영;이용복
    • Journal of Pharmaceutical Investigation
    • /
    • 제38권3호
    • /
    • pp.199-205
    • /
    • 2008
  • Famciclovir, 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine, is an oral prodrug of the antiherpesvirus nucleoside analogue, penciclovir. In human, famciclovir is orally well absorbed and then undergoes extensive first pass metabolism to penciclovir and essentially no parent compound is recovered from plasma or urine. The purpose of the present study was to evaluate the bioequivalence of two famciclovir tablets, Famvir tablet 750 mg (Novartis Korea Ltd.) and Famcivir tablet 750 mg (Hanmi Pharmaceutical. Co., Ltd.), according to the guidelines of the Korea Food and Drug Administration (KFDA). The release of famciclovir from the two famciclovir formulations in vitro was tested using KP VIII Apparatus II method with water. Twenty six healthy male subjects, $23.38{\pm}1.72$ years in age and $68.59{\pm}7.84\;kg$ in body weight, were divided into two groups and a randomized $2{\times}2$ cross-over study was employed. After a single tablet containing 750 mg as famciclovir was orally administered, blood samples were taken at predetermined time intervals and the concentrations of penciclovir in serum were determined using HPLC with UV detector. The dissolution profiles of two formulations ere similar at water. The pharmacokinetic parameters such as $AUC_t$, $C_{max}$ and $T_{max}$ were calculated and ANOVA test was utilized for the statistical analysis of the parameters using logarithmically transformed $AUC_t$, $C_{max}$ and untransformed $T_{max}$. The results showed that the differences between two formulations based on the reference drug, $Famvir^{(R)}$ tablet 750 mg, were -0.53%, 1.12% and -24.82% for $AUC_t$, $C_{max}$ and $T_{max}$, respectively. There were no sequence effects between two formulations in these parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log 0.8 to log 1.25 (e.g., $log\;0.9569{\sim}log\;1.0423$ and $log\;0.8763{\sim}log\;1.2136$ for $AUC_t$ and $C_{max}$, respectively). Thus, the criteria of the KFDA bioequivalence guideline were satisfied, indicating Famcivir tablet 750 mg was bioequivalent to Famvir tablet 750 mg.

Current scenario and future applicability of antivirals against herpes zoster

  • Sang Hun Kim
    • The Korean Journal of Pain
    • /
    • 제36권1호
    • /
    • pp.4-10
    • /
    • 2023
  • Herpes zoster (HZ) is a common disease in the aging population and immunocompromised individuals, with a lifetime risk of 20%-30% that increases with age. HZ is caused by reactivation of the varicella-zoster virus (VZV), which remains latent in the spinal dorsal root ganglia and cranial sensory ganglia after resolution of the primary VZV infection. The main focus of HZ management is rapid recovery from VZV infection as well as the reduction and prevention of zoster-associated pain (ZAP) and postherpetic neuralgia (PHN). The use of antivirals against VZV is essential in the treatment of HZ. However, limited antivirals are only licensed clinically for the treatment of HZ, including acyclovir, valacyclovir, famciclovir, brivudine, and amenamevir. Fortunately, some new antivirals against different types of Herpesviridae have been investigated and suggested as novel drugs against VZV. Therefore, this review focuses on discussing the difference in efficacy and safety in the currently licensed antivirals for the treatment of HZ, the applicability of future novel antivirals against VZV, and the preventive or therapeutic effects of these antivirals on ZAP or PHN.

Current Status of Anti-HBV Chemotherapy

  • Hong, Joon H.;Choi, Yong-Seok;Chun, Byoung K.;Lee, Kyeong;Chu, Chung K.
    • Archives of Pharmacal Research
    • /
    • 제21권2호
    • /
    • pp.89-105
    • /
    • 1998
  • In the past decade, significant progress has been achieved in the battle against hepatitis B virus. In addition to the immunomodulating agents such as interferon-.alpha., and thymosin, many novel antiviral agents have been discovered, among which nucleoside analogues are the mainstay. New-generation compounds such as 3TC and famciclovir have shown promise in the treatment of patients chronically infected by this virus, and are on the line for approval. However, viral rebound after cessation of therapy still remains a major problem. Additionally, the reports on the drug resistance to these antiviral agents suggest that combination therapy will be the eventual strategy (Bartholomew et al., 1997; Tipples et al., 1996). Therefore, developments of safe and effective antiviral agents which do not cross-resist with currently available antiviral drugs are still much needed.

  • PDF

Treatment of herpes zoster with ultrasound-guided superficial cervical plexus block

  • Lee, Hyerim;Jeon, Younghoon
    • Journal of Dental Anesthesia and Pain Medicine
    • /
    • 제15권4호
    • /
    • pp.247-249
    • /
    • 2015
  • Herpes zoster most commonly occurs in elderly patients, and usually affects sensory neurons. Therefore, its characteristic symptoms are segmental pain, itching, and sensory changes in the affected areas. A 71-yr-old woman experienced painful herpetic rash on the right cervical 2-4 dermatomes for 16 days. Two days after the onset of the rash, she was diagnosed with herpes zoster, and prescribed 250 mg famciclovir three times a day for 7 days, pregabalin 150 mg twice a day, and tramadol 150 mg once a day for 14 days, by a dermatologist. Despite medication, her pain was rated at an intensity of 6/10 on the numeric rating scale. In addition, she complained of severe itching sensation on the affected dermatomes. Superficial cervical plexus block (SCPB) was performed at the right C4 level with 15 ml 0.5% lidocaine plus triamcinolone 30 mg. Five days after the procedure, pain and itching completely disappeared. SCPB may be an effective option for the treatment of acute pain and itching arising from herpes zoster, and for the prevention of postherpetic neuralgia.

반대편 눈확위신경 영역에 재발된 대상포진 1예 (Recurrent Herpes Zoster on the Supraorbital Counter Area -A case report-)

  • 손지선;오광조;한영진;이준례;최훈
    • The Korean Journal of Pain
    • /
    • 제14권2호
    • /
    • pp.266-270
    • /
    • 2001
  • An 85-year old female patient visited our pain clinic because of pin pricking pain and allodynia on the left forehead area for 2 days. Vesicular eruptions were seen along the left supraorbital nerve distribution. She experienced similar pain and eruptions on the contralateral forehead, the supraorbital counter area, 8 years previous. She had been taking antihypertensive medications for 15 years. She also had suffered from diabetes mellitus. She received a total hysterectomy and anterior posterior colporrhapy due to procidentia uteri and severe cystocele and rectocele. She had been treated intermittently for back pain due to advanced osteoarthritis and spondylosis. She was treated with famciclovir and triamcinolone acetonide with daily stellate ganglion block and supraorbital nerve block. Nortriptyline (a tricyclic antidepressant) and midazolam was prescribed to relieve pain and difficulty in sleeping. After 3 days, all treatment was ended because it was impossible to assess the severity of pain due to the senile psychosis of the patient. She eventually expired after 2 months. We report this case because it is rare for herpes zoster to recur, and particularly on the contralateral counter area.

  • PDF

Clinical and inflammatory response to antiviral treatments in dogs with parvoviral enteritis

  • Nergis Ulas;Yunusemre Ozkanlar;Seckin Ozkanlar;Mehmet Ozkan Timurkan;Hakan Aydin
    • Journal of Veterinary Science
    • /
    • 제25권1호
    • /
    • pp.11.1-11.16
    • /
    • 2024
  • Background: Canine parvoviral enteritis (CPE) is a fatal disease worldwide. The treatment of CPE is based mainly on supportive and symptomatic treatment. Antiviral addition to the treatment may result in a higher survival. Objectives: This study evaluated the effects of antiviral treatments with a standardized treatment (ST) on the clinical and inflammatory response of dogs with naturally occurring CPE. Methods: Twenty-eight dogs with CPE caused by canine parvovirus type 2 were divided randomly into treatment groups. The ST group received fluid, antibiotic, antiemetic, and deworming treatments. The antiviral treatment groups received the same ST with an additional antiviral drug, recombinant feline interferon omega (rFeIFN-ω), oseltamivir (OSEL) or famciclovir (FAM). Results: Compared to the healthy control, the tumor necrosis factor-α, interleukin-1β, interferon (IFN)-α, IFN-γ, haptoglobin, and C-reactive protein values were high (p < 0.05) on day zero. At presentation, mild lymphopenia, neutropenia, and a high neutrophil to lymphocyte (LYM) ratio (NLR) were also observed. Adding rFeIFN-ω to the ST produced the best improvement in the clinical score with a decreased NLR, while leucocytes remained low and inflammatory markers stayed high on day three. The survival rates of the groups were 85.7% in ST+IFN, 71.4% in ST+OSEL, 71.4% in ST+FAM, and 57.1% in ST groups on day seven. Conclusions: Antiviral drugs may be valuable in treating CPE to improve the clinical signs and survival. In addition, the decrease in NLR in favor of LYM may be an indicator of the early prognosis before the improvement of leukocytes, cytokines, and acute phase proteins in CPE.

Bell's palsy after concomitant chemoradiotherapy: a case report and literature review

  • Sul Gi Choi;Ji Seok Oh;Hoon Myoung;Mi Hyun Seo
    • Journal of Dental Anesthesia and Pain Medicine
    • /
    • 제24권2호
    • /
    • pp.129-135
    • /
    • 2024
  • Concomitant chemoradiotherapy (CCRT) treated patients experience various complications. We present a rare case of post-CCRT Bell's palsy and describe its various possible causes, so as to increase awareness among clinicians about Bell's palsy being a CCRT-associated adverse effect. The patient was a 48-year-old man diagnosed with squamous cell carcinoma who presented with post-CCRT Bell's palsy. After radiotherapy for 6 weeks (overall 67.5 Gy) and four rounds of cisplatin chemotherapy, he complained of paralysis of the entire left face. A test was performed 33 days after the last CCRT session to differentiate Bell's palsy from other causative factors. Based on magnetic resonance imaging findings, facial nerve invasion due to tumor size increase was determined to not cause Bell's palsy. Inflammation of the left Eustachian tube was observed. Hence, steroids and famciclovir were administered, which markedly improved the facial paralysis symptoms within 56 days after facial paralysis development. In conclusion, patients can develop Bell's palsy owing to complex effects of various CCRT mechanisms. Although the exact cause of Bell's palsy has not been identified and the effectiveness of drug treatment was questionable in this case, unlikely causative factors should be excluded through various tests and appropriate and timely measures must be adopted.

모노리틱 칼럼을 이용한 혈장 중 펜시를로버의 HPLC 신속분석법 개발 및 이를 이용한 생물학적동등성시험 (Development of a rapid HPLC method for the determination of penciclovir in human plasma using a monolithic column and its application to a bioequivalence study)

  • 김진희;박아연;정은하;이철우;이태호;염정록
    • 분석과학
    • /
    • 제20권4호
    • /
    • pp.323-330
    • /
    • 2007
  • 본 연구에서는 건강한 성인 혈장 중의 펜시클로버를 모노리틱(monolithic) 칼럼을 이용한 고성능 액체크로마토그래피(HPLC)-형광검출법으로 신속하게 분석하는 방법을 개발하였다. 충전형 ODS 칼럼보다 빠른 유속에서 고분리능을 구현할 수 있는 모노리틱 칼럼을 사용하였고, 이동상에 이온쌍 시약(ionpairing reagent)인 sodium dodecyl sulfate와 잔존 실라놀기(residual silanol group)를 차폐하는 triethylamine을 첨가하여, 용매 조성과 유량에 대한 기울기 용리(gradient elution)를 실시하였다. 그 결과, 펜시클로버와 내부표준물질로 사용한 간시클로버의 머무름시간을 4분 이내로 단축시킬 수 있었다. 확립된 방법으로 분석법 검증을 실시한 결과, $0.1{\sim}5{\mu}g/mL$의 농도 범위 내에서 검량선의 상관계수가 0.9994로 양호한 직선성을 나타내었다. 또한 하루에 5번 반복 실험하여 구한 일내 정밀성과 정확성은 1.36~8.55%, 92.8~100.0%이었고, 5일간 반복 실험하여 구한 일간 정밀성은 0.93~5.62%이었으며, 정량한계는 $0.1{\mu}g/mL$이었다. 건강한 성인 24명을 대상으로한 팜시클로버 제제의 생물학적동등성시험에 본 분석법을 적용하였으며, 생물학적동등성시험 판단기준에 따라 시험약이 대조약에 대하여 동등한 것으로 판명되었다.